scholarly journals Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis

2016 ◽  
Vol 15 (6) ◽  
pp. 783-790 ◽  
Author(s):  
D.R. VanDevanter ◽  
P.A. Flume ◽  
N. Morris ◽  
M.W. Konstan
Keyword(s):  
Cystic Fibrosis ◽  
Antibiotic Treatment ◽  
Pulmonary Exacerbation

scholarly journals Socioeconomic Status and the Likelihood of Antibiotic Treatment for Signs and Symptoms of Pulmonary Exacerbation in Children with Cystic Fibrosis

2011 ◽  
Vol 159 (5) ◽  
pp. 819-824.e1 ◽  
Author(s):  
Michael S. Schechter ◽  
Susanna A. McColley ◽  
Warren Regelmann ◽  
Stefanie J. Millar ◽  
David J. Pasta ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Socioeconomic Status ◽  
Antibiotic Treatment ◽  
Signs And Symptoms ◽  
Pulmonary Exacerbation

scholarly journals Procalcitonin predicts the severity of cystic fibrosis pulmonary exacerbations and readmissions in adult patients: a prospective cohort study

2020 ◽  
Vol 68 (4) ◽  
pp. 856-863
Author(s):  
Kristina L Bailey ◽  
Peter J Murphy ◽  
Olena K Lineberry ◽  
Matthew R Haack ◽  
John D Dickinson ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Antibiotic Treatment ◽  
Hospital Admissions ◽  
Clinical Care ◽  
Forced Expiratory Volume ◽  
Pulmonary Exacerbation ◽  
Inclusion Criteria ◽  
Exclusion Criteria ◽  
Pulmonary Exacerbations ◽  
Time Of Admission

Patients with cystic fibrosis (CF) experience multiple pulmonary exacerbations throughout their lifetime, resulting in repeated antibiotic exposure and hospital admissions. Reliable diagnostic markers to guide antibiotic treatment in patients with CF, however, are lacking. Given that the CF airway is characterized by persistent and frequent bacterial infection, our goal was to determine if procalcitonin (PCT) could be used as a severity and prognostic marker of CF exacerbation. We enrolled 40 participants at the time of diagnosis of CF pulmonary exacerbation. Inclusion criteria: age ≥19 years with exacerbation requiring antibiotics as determined by the treating physician. Exclusion criteria: antibiotics initiated more than 48 hours prior to enrollment, and pregnancy. Blood samples were collected on enrollment day and after 7–10 days of treatment. Of the 40 patients enrolled, 23 (57.5%) had detectable levels of PCT (≥0.05 ng/mL). PCT levels were significantly associated with pulmonary exacerbation scores (p=0.01) and per cent decrease in forced expiratory volume in 1 second (FEV1) (p=0.01) compared with the best in the last 12 months. Those who had worsening PCT during treatment had less improvement in FEV1 (p=0.001) and were more likely to be readmitted to the hospital sooner (p<0.0001). Likewise, those who had a detectable PCT at the time of admission were more likely to be readmitted sooner (p=0.03). PCT elevation during antibiotic treatment is associated with less improvement in FEV1 and earlier readmission. A detectable PCT level occurs only in more severe CF exacerbations. Multicenter trials are needed to confirm whether PCT may play a role in the clinical care of patients with CF.

Quality of Well-Being Before and After Antibiotic Treatment of Pulmonary Exacerbation in Patients with Cystic Fibrosis

CHEST Journal ◽  
1990 ◽  
Vol 98 (5) ◽  
pp. 1081-1084 ◽  
Author(s):  
David M. Orenstein ◽  
Edward N. Pattishall ◽  
Patricia A. Nixon ◽  
Elizabeth A. Ross ◽  
Robert M. Kaplan
Keyword(s):  
Cystic Fibrosis ◽  
Antibiotic Treatment ◽  
Well Being ◽  
Pulmonary Exacerbation ◽  
Before And After

scholarly journals Inflammation in children with cystic fibrosis: contribution of bacterial production of long-chain fatty acids

2021 ◽  
Author(s):  
Erin Felton ◽  
Aszia Burrell ◽  
Hollis Chaney ◽  
Iman Sami ◽  
Anastassios C. Koumbourlis ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Fatty Acid ◽  
Antibiotic Treatment ◽  
Bacterial Production ◽  
Clinical Status ◽  
Achromobacter Xylosoxidans ◽  
List Type ◽  
Future Studies ◽  
Long Chain

Abstract Background Cystic fibrosis (CF) affects >70,000 people worldwide, yet the microbiologic trigger for pulmonary exacerbations (PExs) remains unknown. The objective of this study was to identify changes in bacterial metabolic pathways associated with clinical status. Methods Respiratory samples were collected at hospital admission for PEx, end of intravenous (IV) antibiotic treatment, and follow-up from 27 hospitalized children with CF. Bacterial DNA was extracted and shotgun DNA sequencing was performed. MetaPhlAn2 and HUMAnN2 were used to evaluate bacterial taxonomic and pathway relative abundance, while DESeq2 was used to evaluate differential abundance based on clinical status. Results The mean age of study participants was 10 years; 85% received combination IV antibiotic therapy (beta-lactam plus a second agent). Long-chain fatty acid (LCFA) biosynthesis pathways were upregulated in follow-up samples compared to end of treatment: gondoate (p = 0.012), oleate (p = 0.048), palmitoleate (p = 0.043), and pathways of fatty acid elongation (p = 0.012). Achromobacter xylosoxidans and Escherichia sp. were also more prevalent in follow-up compared to PEx (p < 0.001). Conclusions LCFAs may be associated with persistent infection of opportunistic pathogens. Future studies should more closely investigate the role of LCFA production by lung bacteria in the transition from baseline wellness to PEx in persons with CF. Impact Increased levels of LCFAs are found after IV antibiotic treatment in persons with CF. LCFAs have previously been associated with increased lung inflammation in asthma. This is the first report of LCFAs in the airway of persons with CF. This research provides support that bacterial production of LCFAs may be a contributor to inflammation in persons with CF. Future studies should evaluate LCFAs as predictors of future PExs.

scholarly journals Effect of Antibiotic Treatment on Bacteriophage Production by a Cystic Fibrosis Epidemic Strain ofPseudomonasaeruginosa

2010 ◽  
Vol 55 (1) ◽  
pp. 426-428 ◽  
Author(s):  
Joanne L. Fothergill ◽  
Eilidh Mowat ◽  
Martin J. Walshaw ◽  
Martin J. Ledson ◽  
Chloe E. James ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Antibiotic Treatment ◽  
Epidemic Strain ◽  
Phage Production

ABSTRACTPhage production in response to antibiotics varied among four isolates of aPseudomonasaeruginosacystic fibrosis (CF) epidemic strain. Whereas ciprofloxacin induced higher levels of phage production, other CF-relevant antibiotics led to reduced production. We detected free phages directly in CF patient sputum samples by both plaque (40% positive) and PCR (76% positive) assays. Our observations suggest that the choice of antibiotics could influence the number of free phages within the CF lung environment.

Sign in / Sign up

Export Citation Format

Share Document